<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810741</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201071</org_study_id>
    <nct_id>NCT04810741</nct_id>
  </id_info>
  <brief_title>Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France</brief_title>
  <acronym>RETROBIZH</acronym>
  <official_title>Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schistosomiasis is a major public health issue. Clinical guidelines for the management of&#xD;
      imported schistosomiasis are heterogeneous. The objective of this study is to describe the&#xD;
      clinical management of schistosomiasis imported cases in France, regarding diagnosis,&#xD;
      treatment and follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schistosomiasis is a major public health issue. Clinical guidelines for the management of&#xD;
      imported schistosomiasis are heterogeneous. The objective of this study is to describe the&#xD;
      clinical management of schistosomiasis imported cases in France, regarding diagnosis,&#xD;
      treatment and follow-up. It is a multicentric, retrospective, descriptive study. Inclusion&#xD;
      criteria are an age ≥ 18, a positive western blot and / or a positive microscopy exam. Data&#xD;
      concerning clinical presentation, biological samples, imaging, treatment and follow-up will&#xD;
      be assessed. A descriptive analysis will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the management of patients with chronic schistosomiasis in France, in terms of diagnosis, assessment, management and follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>Draft of new clarified recommendations on the overall management of this pathology</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Schistosomiasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 18 years-old with a diagnosis of schistosomiasis in France&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18, positive schistosomiasis immunoblot and / or positive microscopy examination&#xD;
             for schistosomiasis eggs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Jareguiberry, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephane Jaureguiberry, professor</last_name>
    <phone>01 4521 74 21</phone>
    <email>stephane.jaureguiberry@aphp.fr</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schistosomiasis, retrospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

